Tetrahydrofuran
Medchemexpress LLC Beroterkib anhydrous | 2095719-92-7 | 99.9% | 584.04 g·mol⁻¹ | C29H31ClFN5O5 | 100MG
ASTX029 (beroterkib) is a small-molecule, dual-mechanism inhibitor of extracellular signal-regulated kinases ERK1 and ERK2 developed as a clinical candidate. It potently inhibits ERK catalytic activity and suppresses ERK phosphorylation, showing low-nanomolar biochemical and cellular potency and intended for preclinical research into MAPK-driven cancers. Supplied for research use only.
Medchemexpress LLC Erk1/2 inhibitor 2 (ASTX-029) | 2095719-92-7 | >98.0% | 584.04 g/mol | C29H31ClFN5O5 | 25MG
ASTX029 is a dual-mechanism extracellular signal-regulated kinase (ERK) 1/2 inhibitor developed as a clinical candidate. It inhibits ERK catalytic activity and ERK phosphorylation, with reported ERK2 IC50 ≈ 2.7 nM, and has demonstrated antineoplastic activity in preclinical models and early clinical evaluation. Supplied as a crystalline solid for research use, typical vendor-reported purity is ≥98% (CAS 2095719-92-7).
- Potent dual-mechanism ERK inhibitor with low-nanomolar potency.
- Inhibits both catalytic activity and phosphorylation of ERK.
- Demonstrated antineoplastic activity in preclinical and early clinical studies.
- Supplied as a crystalline solid suitable for in vitro and in vivo formulation.
- Typical purity ≥98% by vendor testing.
- CAS number 2095719-92-7 and molecular weight ≈584.04 g/mol.
- For research use only; not for human therapeutic use.